4.53
0.12 (2.61%)
| Previous Close | 4.41 |
| Open | 4.49 |
| Volume | 486,994 |
| Avg. Volume (3M) | 462,133 |
| Market Cap | 95,025,000 |
| Price / Sales | 3.29 |
| 52 Weeks Range |
| Operating Margin (TTM) | -11,739.09% |
| Diluted EPS (TTM) | -0.060 |
| Quarterly Revenue Growth (YOY) | -87.00% |
| Current Ratio (MRQ) | 0.270 |
| Operating Cash Flow (TTM) | -1.24 M |
| Levered Free Cash Flow (TTM) | -1.25 M |
| Return on Assets (TTM) | -61.74% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Instruments & Supplies (US) | Bearish | Mixed |
| Medical Instruments & Supplies (Global) | Bearish | Bearish | |
| Stock | Cuprina Holdings (Cayman) Limit | - | - |
AIStockmoo Score
| Analyst Consensus | -2.0 |
| Insider Activity | NA |
| Price Volatility | 1.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.0 |
| Average | 0.88 |
|
Cuprina Holdings (Cayman) Ltd is a biomedical and biotechnology company that is dedicated to the development and commercialization of innovative products for the management of chronic wounds, as well as operating in the health and beauty sector. It manufactured and distributed a line of medical grade sterile blowfly larvae bio-dressing products marketed under the MEDIFLY brand name, or the MEDIFLY products. The MEDIFLY products are used as a biological debridement tool for chronic wounds, in a procedure known as Maggot Debridement Therapy, or MDT, which is an effective alternative to surgical debridement. |
|
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |